Multiple Myeloma Survival Rate After Stem Cell Transplant

Most people with multiple myeloma who undergo an autologous stem cell transplant survive well beyond the five-year mark, though individual outcomes vary widely depending on genetic risk, depth of response, and post-transplant treatment. In one analysis, the one-year overall survival after transplant was about 93%, and three-year survival was roughly 77%. Those numbers have climbed steadily over the past three decades, and the story behind that improvement involves several interlocking factors that are worth understanding if you or someone you care about is facing this decision.

Where the Numbers Stand Today

Autologous stem cell transplant, where your own stem cells are collected and returned after high-dose chemotherapy, remains the standard approach for eligible myeloma patients. A single-center study reported one-year overall survival of about 93% and three-year overall survival of roughly 77%, with progression-free survival tracking closely at those time points.¹ Longer-term data show that a meaningful number of patients survive a decade or more. Among long-term survivors with a median follow-up of 13 years from diagnosis, the 15-year overall survival rate was 62%, though only about 19% remained progression-free at that point.² That gap between overall survival and progression-free survival tells an important story: many patients relapse but go on to live for years with subsequent treatments.

These numbers have improved dramatically over time. A large real-world study spanning three decades found that median progression-free survival rose from about 22 months for patients transplanted between 1988 and 2000 to nearly 59 months for those transplanted between 2016 and 2021. Overall survival climbed from a median of about 55 months in the earliest era to a median that had not yet been reached in the most recent group, meaning more than half of those patients were still alive at the end of follow-up.³ These gains came despite transplant recipients getting older and sicker on average, driven largely by better drugs given before and after the transplant itself.

How Genetic Risk Changes the Picture

Not all myeloma behaves the same way. Certain chromosomal abnormalities in the cancer cells, often called high-risk cytogenetics, predict shorter remissions and shorter survival. A large registry analysis found that three-year progression-free survival after transplant was 37% in high-risk patients compared with 49% in standard-risk patients, and three-year overall survival was 72% versus 85%.⁴ In another study, median progression-free survival for high-risk patients was only about 10 months versus over 32 months for standard-risk patients, and median overall survival was 28 months versus a figure that hadn’t been reached.⁵

Even within the high-risk group, outcomes are not uniform. Having only one high-risk chromosomal abnormality rather than two or more is independently associated with better survival. And the specific abnormality matters. Patients with a translocation known as t(4;14) who achieved deep responses and cleared residual disease after transplant had significantly better progression-free and overall survival, but patients with deletion of chromosome 17p or with two or more high-risk abnormalities did not see the same benefit from deep response, suggesting those biology subtypes are particularly aggressive.⁶

Why Clearing Residual Disease Matters So Much

One of the strongest predictors of how long a transplant will keep myeloma in check is whether the cancer becomes undetectable at a molecular level afterward, a status called minimal residual disease (MRD) negativity. Sensitive laboratory tests can detect as few as one myeloma cell among a million normal cells, and patients who reach that threshold consistently do better. In a study of patients who received transplant followed by lenalidomide maintenance, those who were still MRD-positive one year after transplant had roughly three and a half times the risk of disease progression and a similarly elevated risk of death compared with MRD-negative patients.⁷

A separate analysis confirmed the pattern: MRD-positive patients had about double the risk of progression and a significantly higher risk of death than those who tested negative.⁸ The clinical takeaway is that MRD testing is becoming a practical tool for doctors to decide how aggressively to treat after transplant. If residual disease is detected, the treatment plan may need adjustment; if it is negative, the current approach is working.

Does Age Limit Who Should Get a Transplant?

Myeloma is most often diagnosed in people in their late 60s and 70s, which raises an obvious question: is transplant safe and effective for older patients? The answer is nuanced. In one large study comparing patients 70 and older with younger patients, five-year overall survival was 56% in the older group versus 73% in the younger group, and one-year treatment-related mortality was higher among older patients (about 4% versus 1%).⁹ Older age predicted shorter survival in a statistical model, though the five-year mark above 50% is still a meaningful result for a disease with a historically poor prognosis.

A matched-pair analysis painted an even more encouraging picture for carefully selected older patients. When researchers compared patients over 70 with younger patients who had similar disease characteristics, the overall response rates were nearly identical (97% versus 98%), and median overall survival from transplant had not been reached in the older group at the time of analysis. Transplant toxicity was comparable too.¹⁰ The lesson is that calendar age alone should not rule out transplant. Fitness, organ function, and overall health matter more than a number on a birthday card.

Maintenance Therapy After Transplant

The transplant itself is one piece of the puzzle. What happens afterward may be equally important. Lenalidomide maintenance, a low-dose oral medication taken continuously after transplant, has become standard care based on strong evidence. A meta-analysis of randomized trials found that patients on lenalidomide maintenance had a median progression-free survival of nearly 53 months compared with about 24 months for those on placebo or observation. At a median follow-up of about 80 months, median overall survival had not been reached in the lenalidomide group versus 86 months in the control group, translating to a 25% reduction in the risk of death.¹¹

Individual trials tell a consistent story. One landmark trial showed lenalidomide maintenance nearly doubled the median time to progression, from 23 months with placebo to 41 months, with the benefit holding across all patient subgroups.¹² Another found a similar benefit with fewer deaths in the lenalidomide arm (15% versus 23%).¹³ Newer agents are being tested in this space as well. A phase 3 trial of daratumumab maintenance after transplant found that it cut the risk of progression or death roughly in half compared with observation alone.¹⁴

The Melphalan Dose Question

Before stem cells are infused back, patients receive high-dose melphalan chemotherapy to wipe out as much myeloma as possible. The standard dose is 200 mg/m², but some patients, particularly those who are older or have kidney problems, receive a reduced dose of 140 mg/m². Whether this lower dose compromises outcomes has been studied repeatedly, and the answer is reassuring for patients who need the reduction. A large collaborative study found no significant differences in overall survival, progression-free survival, or relapse rates between the two doses. The one exception: patients who were transplanted with a poor response to pre-transplant therapy did better with the higher dose.¹⁵ More recent studies confirmed comparable two-year outcomes and MRD negativity rates between doses.¹⁶

How Many Stem Cells You Get Back

A less discussed factor is how many stem cells are infused. The minimum threshold for adequate blood count recovery is about 2 million CD34+ cells per kilogram of body weight, but higher doses appear to improve long-term outcomes. A study found that patients receiving at least 5 million CD34+ cells per kilogram had significantly better progression-free survival, overall survival, deeper responses, and higher rates of sustained MRD negativity. The benefit plateaued above about 10.6 million per kilogram, so there appears to be a sweet spot rather than a “more is always better” relationship.¹⁷ Another study looking at long-term follow-up found that patients who received fewer than 5 million cells per kilogram had a median overall survival of about 103 months compared with 145 months for those who received more.¹⁸

Tandem Transplant and Timing Decisions

For years, a second “tandem” transplant shortly after the first was considered for high-risk patients. Real-world data now challenge that approach. A Canadian study found that single and tandem transplants produced essentially identical outcomes: median progression-free survival of about 35 months in both groups and median overall survival of 93 and 89 months, respectively, with no significant difference. This held regardless of the type of chromosomal abnormality or maintenance therapy used.¹⁹ The authors attributed the disappearance of tandem transplant’s benefit to the routine use of effective maintenance therapy, which may achieve the same extended disease control without the toxicity of a second procedure.

Another common question is whether transplant should happen right away or can be deferred until relapse. Long-term follow-up of the IFM 2009 trial showed that eight-year overall survival was about 60% in patients who delayed transplant and 62% in those who received it upfront, with no significant difference.²⁰ A smaller study reached a similar conclusion, finding comparable three- and five-year overall survival for early and late transplant when modern induction drugs were used.²¹ This gives patients and doctors some flexibility, though upfront transplant is still the most common approach in practice because it typically achieves deeper responses and longer first remissions.

Allogeneic Transplant Is a Different Calculation

Allogeneic transplant, using a donor’s stem cells instead of your own, is far less commonly performed in myeloma and comes with substantially higher risks. A large analysis of allogeneic transplant outcomes reported a median overall survival of just 1.7 years. Three-year overall survival was about 38%, five-year survival was roughly 22%, and treatment-related mortality in the first year was about 24%.²² However, a separate study found that in carefully selected patients, the survival curves flattened after about ten years, with a 10-year overall survival of roughly 28% and relatively low treatment-related mortality of about 8% in the first year.²³ The plateau in those curves is intriguing because it hints that some patients may be functionally cured through the immune system’s ongoing attack on any remaining myeloma cells. Still, allogeneic transplant is generally reserved for young patients who have already failed autologous approaches, given the higher upfront mortality.

What Happens When Myeloma Comes Back After Transplant

How quickly myeloma returns after transplant matters enormously for what comes next. Early relapse, typically defined as within 12 months of transplant, predicts significantly worse outcomes. A study found that patients who relapsed within a year had a median overall survival of only 26 months from that point, compared with 91 months for patients who relapsed later, even though both groups had equal access to salvage therapies.²⁴ Early relapse tends to cluster in patients with high tumor burden and aggressive genetic features, underscoring why risk stratification before transplant is so important.

Even among later relapsers, the road after relapse is challenging. A Spanish registry study of 280 patients who relapsed after transplant reported that only about 30% responded to subsequent treatment, and median overall survival from the time of relapse was 14 months.²⁵ That said, this data predates many of the newer treatments now available for relapsed myeloma, including CAR-T cell therapy and bispecific antibodies, which have improved post-relapse survival in more recent cohorts.

Quality of Life Recovery

Survival numbers only tell part of the story. Transplant is physically punishing in the short term, and patients reasonably want to know how they will feel afterward. Research consistently shows that quality of life takes a hit during and immediately after transplant but recovers quickly. A review of available studies found that the low point is short-lived, with most patients returning to their pre-transplant baseline within one to two months. Longer term, quality of life often exceeded pre-transplant levels, likely because better disease control reduced symptoms from the myeloma itself.²⁶

A longitudinal study tracking patients over four years confirmed that overall quality-of-life scores improved between enrollment and one year after transplant and then remained stable. The proportion of patients reporting low symptom burden actually increased from 27% before transplant to 38% at one year. However, a substantial number of survivors continued to report moderate or severe individual symptoms, such as fatigue and pain, at one year and beyond.²⁷ So while the overall trajectory is positive, lingering symptoms are common and worth planning for.

Secondary Cancers and Other Late Effects

Long-term survivors face an elevated risk of developing a second, unrelated cancer. A study following transplant recipients for a median of nearly five years found that about 5% developed an invasive secondary malignancy within five years, 12% within ten years, and 21% within twenty years. These included both blood cancers and solid tumors, though roughly half of the solid tumors were caught at an early, curable stage.²⁸ A large Korean population study added that transplant-eligible myeloma patients had a modestly higher rate of any secondary malignancy compared with transplant-ineligible patients.²⁹ This risk is real but needs to be weighed against the substantial survival benefit of transplant. For most patients, the benefit far outweighs the incremental cancer risk, but it does reinforce the importance of routine cancer screening in long-term survivors.

Real-World Outcomes Versus Clinical Trials

If you have been reading about myeloma clinical trials and comparing those numbers to what your doctor quotes, you may notice a gap. That is not unusual. A Canadian real-world analysis found that progression-free survival in their transplant population was shorter than what the landmark DETERMINATION clinical trial reported, even though the real-world data started counting from a later time point. The authors attributed this to the fact that real-world patients include people with kidney problems, severe blood-count issues, older age, and other complications that would have excluded them from the trial.³⁰ Clinical trial participants are typically younger, fitter, and more closely monitored than average patients. That is worth remembering when interpreting the statistics cited in this article or anywhere else.

Who Gets Access and Who Does Not

Survival after transplant depends partly on getting a transplant in the first place, and access is not equal. A population-based analysis of California patients found that Black patients were about 30% less likely to undergo transplant than white patients even after adjusting for age, insurance, comorbidities, and neighborhood socioeconomic status. Patients with lower socioeconomic status and those on Medicaid were less likely to receive early transplant, though lower socioeconomic status did not prevent transplant altogether, suggesting some economic barriers delayed rather than blocked access.³¹ Given the well-established survival benefit of transplant, these disparities translate directly into survival disparities. Expanding access remains one of the clearest opportunities to improve myeloma outcomes at a population level.